Pixium hires new CEO and director

Pixium has appointed Khalid Ishaque as CEO and director. Previously, Ishaque worked at Boston Scientific where he most recently served as general manager of its neuromodulation international business. Based in Paris, Pixium is a maker of vision restoration systems for the blind. Its backers include Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Bpifrance, Seventure and Polytechnos.

Pixium Vision raises funds led by Sofinnova

Pixium Vision, a developer of innovative retinal implant systems, has closed a Series A extension financing. This round was led by Sofinnova Partners, with support from Bpifrance, through the InnoBio fund, and existing series A investors Omnes Capital and Abingworth. In conjunction with the financing, Antoine Papiernik at Sofinnova Partners and Chahra Louafi at Bpifrance have joined the Pixium board of directors.

eFFECTOR Therapeutics Raises $45 Million Series A

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Avedro Completes $43m Series D

Avedro has completed a $43 million Series D financing led by Abingworth along with a significant investment by Third Point. Avedro’s other investors include Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Partners, Borealis Ventures and Echelon Ventures. As part of the transaction, David Mayer from Abingworth and Jason Hong, PhD from Third Point will be joining the board of directors.

Labcyte Closes $5.3m Financing

Labcyte, a privately-held company advancing acoustic liquid handling, has closed a Series D financing led by the healthymagination fund, a part of GE Ventures. The $5.3 million round also included current Labcyte investors – Abingworth, Alloy Ventures, Cross Atlantic Partners, Delphi Ventures, H&Q Healthcare Investors and H&Q Life Sciences Investors.

Celgene to Acquire Avila Therapeutics

Summit, New Jersey-headquartered Celgene Corporation is to acquire Avila Therapeutics, a privately held biotechnology company. Avila is backed by Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. PRESS RELEASE Celgene Corporation (NASDAQ: CELG) and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through […]

Prosensa Raises Funding Round

Prosensa, a Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases, has raised €23 million (US$29.8 million) in new equity financing. The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital. PRESS RELEASE Prosensa, the Dutch biopharmaceutical […]

Takeda Pharmaceutical Buys VC-Backed Intellikine

Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Intellikine Adds $4M in Milestone Payments

Biopharma company Intellikine Inc. has sealed $4 million in new milestone payments as it begins two Phase 1 clinical trials of its drugs. The company, based in La Jolla, Calif., is backed by $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

PEHUB Community

Join the 12494 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget